Market Overview

Alnylam Pharma Reports Offering of $125M in Stock

Related ALNY
Alnylam Begins Phase 1 Clincial Trial For ALN-AS!
After-Hours Movers Friday: Seventy Seven Energy, Kite Pharma
Alnylam (ALNY) Begins Phase I Study on Liver Disease Drug - Analyst Blog (Zacks)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $125 million. All of the shares in the offering are to be sold by Alnylam.

Posted-In: News Offerings


Related Articles (ALNY)

Around the Web, We're Loving...